Applied StemCell (ASC) develops gene-editing platforms and therapeutics enabled by its proprietary TARGATT™ and CRISPR/Cas9 technologies. The company produces enabling tools and leverages genome editing for animal and cell model generation. ASC says it is building a therapeutic pipeline with a strong focus on monogenic blood disorders and high genetic-penetrance diseases. It also emphasizes expanding and strengthening its intellectual property portfolio around improved genome-editing technologies. Management frames the work as enabling scientific discovery and advancing human medicine through both products and therapeutics. The company is based in Milpitas, California.

Total raised

$19M

Funding rounds

1

Latest round

Series D

Latest activity

Jun 2016